Imutex Joint Venture

Imutex Limited

Imutex Limited (Imutex), hVIVO’s 49% owned joint venture with SEEK Group (SEEK), is developing two novel vaccine candidates, FLU-v and AGS-v. FLU-v is a first-in-class ‘universal’, broad spectrum, standalone, flu vaccine candidate which is supported by a compelling data package.

AGS-v is a mosquito-borne disease vaccine with a novel proposed dual action mechanism of
preventing infection in humans whilst controlling the mosquito population.

FLU-v First-in-class universal, broad spectrum, standalone, flu vaccine candidate

AGS-v Universal mosquito-borne diseases vaccine candidate